Esperion Therapeutics Inc (ESPR)

[ClarkKant]

$ESPR going to $40 round 2

[ClarkKant]

Sold $35 let it correct, ride the next wave.

[ClarkKant]

Damn, the 3k shares bought a couple hours before close are looking nice now.

[Wheatcrumb]

It's over $30 in pre-market.

[ClarkKant]

Will be back above $26 this week.

[BuckeyeMike]

Here's a good DewTheDil Link:

http://www.esperion.com/targeting-unmet-needs/

[BuckeyeMike]

http://www.bioworld.com/content/fourier-clinical-benefit-yes-cost-benefit-no-0

Repatha's cost would be about $14,500 a year. ESPR ETC-1002 is only $3,000 a year. And Orally vs. Shot. And less Inflammation.

[BuckeyeMike]

Over reaction.

[DewDiligence]

ESPR was the hardest-hit company yesterday in the fallout from AMGN's Repatha-CVOT presentation:

#msg-129644330

How do you explain that?

[BuckeyeMike]

$ESPR bempedoic acid ETC-1002:

-much lower cost,

-lowers hsCRP/inflammation

-better safety profile

-orally effective

-suited4 statin-intolerant Pts

[STOCK_MOMO]

ESPR monster. Love the swing trading on this one

[PAC]

ESPR 20.5 premarket. Shorting on open para or looking for green red

[DewDiligence]

Despite today's 29% pop, the Repatha CVOT is not necessarily a big win for LDL-lowering drugs—see #msg-128416849.

[STOCK_MOMO]

$14.35 hod, beast

[STOCK_MOMO]

13.89 nice close. ESPR low float monster

[STOCK_MOMO]

Sweet flips

[ClarkKant]

They missed their end of September line.

It will probably be another week or so before we hear anything.

[RottenandDemented]

Buy? mmm what?

[Montecash]

News by Friday buy!!

[RNsidersbuying]

Looking for $8's to make 1st entry at which time the already strong callbids should get even stronger - then would look to write some calls?

Do you have a $$$ entry point here?

[Whalatane]

Dew Have U looked at PRTO ?

My wife works with dialysis patients , she did CKD research at Yale.
Her Renal Dept has been recruiting for PRTO's PATENCY 1 and PATENCY 2 trials .

These trials are double blinded, folks ...no insider info here .

Anyway Dew I'll give you what I have and would appreciate your comments .

Novartis originally had an option on their program ( to improve / maintain patency ( blood flow ) in fistulas , essential for dialysis )
They declined to exercise their option $550m ...or at least they couldn't come to terms .

PRTO IPO'd at $10 a share in 2014 and went ahead on their own ...almost sound like the ZSPH story ( hyperkalemia )
Phase 3 PATENCY 1 was enrolled ahead of schedule and should read out in Dec 2016
Phase 3 PATENCY 2 seemed to have a slowed / delayed enrollment ...may be related to slight change/emphasis in end points ...see clinicaltrials.gov history of changes but is up and running now.

PRTO has funds thru 2017 ...enough to finish PATENCY 1 , but not enough to finish PATENCY 2 . Believe their program is Fast Tracked and also Orphan Drug designated..
PRTO presented at a recent conference ...Webcast is available thru their web site
They also filed a CT order ... SEC confidential treatment order..so I'm wondering if they are back in talks with Novartis ...who you may know has a presence in Renal.

Believe its now Abingworth LLP's 2nd largest position .
Baker Bros and Alta Partners also have positions .

So about Fistula's ( AVF ) and dialysis .
Fistula blockage is a major problem for dialysis patients . My wife deals with it every week. Some of her patients have fistula tracks completely up both arms ...as one fails they start a new one higher up.
Hospitals spend around $17,000 per dialysis patient maintaining or reworking fistula's...PRTO's figures.
So there is a real demand for anything that will reduce Fistula failure.
PRTO thinks they can reduce Fistual failure by 20-30 % with their Vonapantise drug ( applied during creation of the Fistula )

Would appreciate your comments
PRTO has spiked recently ( post conference and CT order )
Thx
Kiwi

PS for anyone else reading this . If their P 3 trial fails , this stock is going to a $1. Risk only what you can afford to lose.

[DewDiligence]

Typo: Meant to say surrogate marker (not market).

[STOCK_MOMO]

10.47 not bad

[STOCK_MOMO]

$9.66 close. Should bounce.

[DewDiligence]

LDL not an ironclad surrogate market, FDA says: #msg-123585201.

[TheFinalCD]

http://ih.advfn.com/p.php?pid=nmona&article=71840639&symbol=ESPR

[DewDiligence]

RBC drastically cuts price target: #msg-119158985.

[BuckeyeMike]

Hello Stocktrademan. You looking to buy or sell short?

[stocktrademan]

$ESPR recent news/filings

bearish 26.75

## source: finance.yahoo.com

Fri, 13 Nov 2015 18:04:21 GMT ~ ESPERION THERAPEUTICS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=espr
*********************************************************

Thu, 12 Nov 2015 23:49:17 GMT ~ Lightning Round: It's nowhere near bottoming yet


read full: http://www.cnbc.com/id/103164511?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103164511
*********************************************************

Thu, 12 Nov 2015 23:25:00 GMT ~ Cramer: I'm staying away from solar


read full: http://finance.yahoo.com/video/cramer-im-staying-away-solar-232500149.html
*********************************************************

Fri, 06 Nov 2015 14:04:19 GMT ~ Esperion Therapeutics to Present at November Healthcare Conferences

[at noodls] - November 6, 2015 ANN ARBOR, MI -- (Marketwired) -- 11/06/15 -- Esperion Therapeutics, Inc.(NASDAQ: ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density ...

read full: http://www.noodls.com/view/469E1EE69725B2494C35AFD0D6048130A1504775
*********************************************************

Fri, 06 Nov 2015 13:30:00 GMT ~ Esperion Therapeutics to Present at November Healthcare Conferences

[Marketwired] - Esperion Therapeutics, Inc. , a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients ...

read full: http://finance.yahoo.com/news/esperion-therapeutics-present-november-healthcare-133000217.html
*********************************************************

$ESPR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ESPR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ESPR/company-info
Ticker: $ESPR
OTC Market Place: Not Available
CIK code: not found
Company name: Esperion Therapeutics, Inc.
Incorporated In:

Business Description:

$ESPR share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$ESPR extra dd links

Company name: Esperion Therapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ESPR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ESPR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ESPR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/news - http://finance.yahoo.com/q/h?s=ESPR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ESPR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ESPR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ESPR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Esperion+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Esperion+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Esperion+Therapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ESPR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ESPR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ESPR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ESPR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ESPR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ESPR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ESPR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ESPR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ESPR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ESPR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ESPR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ESPR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ESPR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ESPR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ESPR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ESPR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ESPR



$ESPR DD Notes ~ http://www.ddnotesmaker.com/ESPR

[bullrider2]

Still that $4 plus ESPR bounce was a beauty today.

[DewDiligence]

The PM bounce was due to LLY’s announcing that evacetrapib failed:

#msg-117649036

[bullrider2]

Not today. We got a very nice bounce before market. I will see what happen after the market open before taking profits. I have a nice 3.75 gain.

[oxnous]

So many biotechs are Lotto tickets. The shorts have been celebrating here for awhile.

[gixxer11]

Jesus this pos lost $100 in value in 5 months

[Wifesmoney]

Looking for a nice bounce

[TheInvincibleBull]

$ESPR what is going on with this? Why the huge drop?

[Wifesmoney]

Got a starter here see what happens

[BuckeyeMike]

I think both statements are true. Here's a difficulty I think many Investor's are having with today's language on the FDA's position on CVOT:

$ESPR's previous PR and this one, unfortunately. Which is:

"…will not require (CVOT)"

vs

"…(CVOT) could be required."

That's a pretty big discrepancy from what they originally communicated to investors versus what they said today with HUGE a implication.

Management screwed up.

[DewDiligence]

Company hasn't been communicating to investors, which doesn't help.

Actually, the reverse is true, IMO. ESPR held an investor CC in August (after the end-of-phase-2 meeting) when it would have been much better to remain silent until receiving the FDA’s written minutes of the meeting (which is what triggered today’s CC).

[BuckeyeMike]

Company hasn't been communicating to investors which doesn't help.
I know the company can't say much but how about "we remain as enthusiastic as ever and look forward to updating shareholders..."

Short interest report just out: 4,110,783 shares short
http://www.nasdaq.com/symbol/espr/short-interest

Could get real interesting depending on what's cooking / partnership? buyout? and the FDA minutes due out any day before the end of the month.

[DegenerateGambler]

Not so interesting, down 3 (7%) to $42.3. This is unbelievable, from over In the hundreds for for 3 months THIS year to the $40s which no real change to the pipeline. Can anyone please explain? Hillary Clinton? She'll never get my vote!

[BuckeyeMike]

Solid couple of days... the next few days should be interesting.

[johnny canuck]

What a POS:(

[SealTheDeal]

Looks to be stabilizing here. Might take a small starter Monday with a wide stop at $43

[pleeb01]

Ok thank you.

[BuckeyeMike]

Between now and the end of the month

[pleeb01]

What time is the report due out please?

[BuckeyeMike]

espr $ESPR short interest report out: 4.280,900 shares short http://www.nasdaq.com/symbol/espr/short-interest

just waiting on the FDA meeting minutes...

[BuckeyeMike]

Grabbed some shares today. Details of FDA meeting minutes out soon....

Short Interest report our tomorrow....

[SealTheDeal]

30's definitely possible based on the chart. Broken through all major support